I say IOS you say AOS:comparative bias in respiratory impedance measurements by Kuo, Chris et al.
                                                              
University of Dundee
I say IOS you say AOS
Kuo, Chris; Jabbal, Sunny; Lipworth, Brian
Published in:
Lung
DOI:
10.1007/s00408-019-00247-y
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Kuo, C., Jabbal, S., & Lipworth, B. (2019). I say IOS you say AOS: comparative bias in respiratory impedance
measurements. Lung, 197(4), 473-481. https://doi.org/10.1007/s00408-019-00247-y
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 10. Sep. 2019
Vol.:(0123456789) 
Lung 
https://doi.org/10.1007/s00408-019-00247-y
RESPIRATORY PHYSIOLOGY
I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance 
Measurements
Chris RuiWen Kuo1 · Sunny Jabbal1 · Brian Lipworth1 
Received: 12 March 2019 / Accepted: 24 June 2019 
© The Author(s) 2019
Abstract
Background The forced oscillation technique (FOT) measures respiratory impedance during normal tidal breathing and 
requires minimal patient cooperation.
Objective To compare IOS and AOS devices in patients with asthma and COPD.
Methods We compared two different FOT devices, namely impulse oscillometry using a loudspeaker (IOS: Jaeger Mas-
terscreen) and airwave oscillometry using a vibrating mesh (AOS: Thorasys Tremoflo) for pre- and post-bronchodilator 
measurements in 84 patients with asthma and COPD.
Results The overall pattern of measurement bias was for higher resistance with IOS and higher reactance with AOS, this 
being the case in asthma and COPD separately. There were small but significantly higher values using IOS for resistance 
at 5 Hz (R5) and 20(19) Hz (R20(19)). In converse, values for reactance at 5 Hz (X5), reactance area (AX) and resonant 
frequency (Fres) were significantly higher using AOS but to a much larger extent. The difference in AX between devices 
was more pronounced in COPD than in asthma. Salbutamol reversibility as % change was greater in asthma than COPD 
patients with AX but not FEV1.
Conclusion Our study showed evidence of better agreement for resistance than reactance when comparing IOS and AOS, 
perhaps inferring that AOS may be more sensitive at measuring reactance in patients with airflow obstruction.
Keywords Impulse oscillometry · Airwave oscillometry · Asthma · COPD · Spirometry · Asthma control questionnaire
Introduction
Current guidelines for asthma and COPD advocate the use 
of spirometry to quantify the degree of airflow obstruction 
[1, 2]. Spirometry involves performing an artificial forced 
expiratory manoeuvre from total lung capacity to resid-
ual volume. As such spirometry induces volume depend-
ent small airway closure. Patients often find it difficult to 
perform an adequate procedure forcibly breathing out all 
the way to residual volume, especially in those who are 
coughing or breathless. Hence, an alternative easier way of 
assessing lung function is required for patients with asthma 
and COPD.
One such method is the so-called forced oscillation tech-
nique (FOT) which was originally described by Dubois [3] 
using a single frequency and subsequently refined with mul-
tiple frequencies by Michaelson [4]. FOT involves meas-
uring the pressure/flow (kPa/l.s) relationship while forced 
oscillations of sound waves are imposed upon normal tidal 
breathing to determine respiratory impedance [5]. Differ-
ent FOT methods have been developed with two commonly 
used commercial devices being impulse oscillometry using 
a loudspeaker source (IOS, Jaeger Masterscreen, Carefu-
sion Hoechberg, Germany) and airwave oscillometry using 
a vibrating mesh (AOS, Tremoflo, Thorasys, Montreal).
The application of IOS to asthma and COPD has been 
previously described in detail elsewhere [6, 7]. In brief the 
nature of the sound waveform determines the frequencies 
at which the respiratory impedance is measured within the 
bronchial tree. Both methods can be crudely thought of as 
being akin to bronchial sonar using bidirectional harmonic 
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sound waves between 5 and 35 Hz. The measured respira-
tory impedance in turn comprises components of in-phase 
resistance (R) and out-of-phase reactance (X). For the resist-
ance component of impedance, the measurement at 5 Hz 
(R5) is thought to reflect the total lung resistance, while at 
20 Hz (R20) reflects central lung resistance. The difference 
between resistance at 5 Hz and 20 Hz (R5–R20) represents 
the frequency-dependent heterogeneity and in essence refers 
to peripheral lung resistance (i.e. total minus central)[8], 
which in turn is related to long-term asthma control [9].
The reactance component reflects the balance of inertial 
and elastic properties of the distensible lung tissue and air-
ways. This is normally measured at a low frequency of 5 Hz 
(X5) which is denoted as a negative value, along with the 
area under the reactance curve (AX) between 5 Hz and the 
resonant frequency (Fres) where the reactance curve crosses 
the zero line. AX essentially represents where elastance 
surpasses inertance at lower frequencies, with higher val-
ues (denoted as positive numbers) reflecting reduced lung 
compliance and hence stiffer lungs. Pointedly AX has been 
shown to be related to exacerbations of COPD as well as 
to asthma control [10–13]. In asthma, changes in AX and 
R5 are concordant in relation to increasing disease severity, 
while AX is more affected than R5 in relation to disease 
severity in COPD [14–16]. R5–R20 and AX in particular are 
thought to reflect changes in the more distal small airways, 
the so-called quiet zone of the lung [17].
The primary objective of the present study was to com-
pare head to head the IOS and AOS devices in patients with 
asthma and COPD.
Patients and Methods
Retrospectively we evaluated IOS and AOS readings of a 
cohort of 84 adult patients who voluntarily attended our 
centre for potential screening into clinical trials. Patients 
included into this study had established diagnosis of either 
asthma or COPD and were all on prescribed inhaler therapy 
at the time of visit. During the visit, spirometry, IOS and 
AOS were performed and asthma patients were asked to 
complete the six point Asthma Control Questionnaire (ACQ) 
[18, 19]. Spirometry (Micromedical, Chatham, United King-
dom) was performed in triplicate according to European 
Respiratory Society guidelines, always done after IOS and 
AOS measurements. IOS and AOS measurements were done 
in random order and performed in triplicate according to 
guidelines [5] using Jaeger Masterscreen IOS system and 
Thorasys TremoFlo AOS system. Accuracy of resistance 
measurements was confirmed on each day with a 3L cali-
bration syringe and a standard 0.2 kPa/l.s resistance mesh.
For both IOS and AOS, participants were seated wear-
ing a nose clip, with both hands supporting their cheeks 
with normal tidal breathing. IOS, AOS and spirometry were 
measured before and after bronchodilator as inhaled salbu-
tamol 400 µg.
Following 40 s of tidal breathing for IOS and 20 s for 
AOS, measurements of R5, R20 (R19 for AOS), Fres, AX 
and X5 were generated. Each test was inspected for arte-
facts and a minimum of three measurements were obtained. 
Readings with coherence values of ≥ 0.7 at 5 Hz were con-
sidered acceptable and a between test coefficient of variation 
of Zrs < 15%. In cases where Fres > 35 Hz, we considered 
that the associated AX values could not be properly calcu-
lated and hence such measurements were excluded from the 
dataset, although those for X5 remained valid. As the default 
setting for the Tremoflo device measures resistance at 19 Hz 
(R19), we compared R20 for IOS versus R19 for AOS in 
all subjects, and in a subgroup of n = 58 subjects, after a 
subsequent software update, we were able to also ascertain 
R20 for AOS and hence directly compare with R20 for IOS.
Statistical Analysis
The data were initially inspected for normal distribution. 
Bland–Altman analysis was applied to identify the com-
parative bias between the measurements of two devices. 
The Bland–Altman data for differences were then analysed 
with linear regression models to evaluate the degree of bias 
between IOS and AOS measurements. Comparisons of mean 
differences between devices were performed using pairwise 
Student’s t tests. Linear regression models were also sepa-
rately applied to IOS and AOS measurements to assess the 
model fit. In addition, linear regression was applied to exam-
ine the relationship between AX versus  FEV1% predicted 
and versus ACQ, the latter only in asthma patients. p Values 
are quoted as < 0.05, < 0.01, < 0.001.
Results
Demographic data on the combined and separate asthma 
and COPD groups are shown in Table 1. As expected, 
this showed that patients with COPD had lower  FEV1 
(p < 0.001), FEF25-75 (p < 0.001),  FEV1/FVC ratio 
(p < 0.001); higher R5–R20(19) (p < 0.05), AX (p < 0.001) 
and Fres (p < 0.05); lower X5 (p < 0.05) values compared to 
those with asthma. Patients with COPD were heavier smok-
ers, while asthma patients were more atopic. Mean coher-
ence values for impedance at 5 Hz and 20 Hz were 0.80 and 
0.94 respectively for IOS and 0.89 and 0.95 for AOS.
Bland–Altman plots for resistance revealed good agree-
ment between IOS and AOS with R5 and R20 (Fig. 1). 
Regression analysis of the Bland–Altman differences 
between devices showed a weakly significant poor model 
Lung 
1 3
Ta
bl
e 
1 
 D
em
og
ra
ph
ic 
da
ta
Sm
ok
in
g s
tat
us
 n/
e/c
 =
 no
n/
ex
/cu
rre
nt
 sm
ok
er,
 IC
S 
as
 be
clo
m
eth
as
on
e µ
g e
qu
iv
ale
nt
 do
se
SP
T 
sk
in
 p
ric
k 
tes
t, 
LA
BA
 lo
ng
 ac
tin
g 
β2
 ag
on
ist
, L
AM
A 
lo
ng
 ac
tin
g 
m
us
ca
rin
ic 
an
tag
on
ist
, L
TR
A  
leu
ko
tri
en
e r
ec
ep
to
r a
nt
ag
on
ist
, T
H
EO
 th
eo
ph
yl
lin
e, 
O
AH
 o
ra
l a
nt
ih
ist
am
in
e. 
Th
e c
on
ve
rsi
on
 
fac
to
r f
ro
m
 kP
a t
o  c
m
H 2
O 
is 
× 
10
.2
Ov
er
all
N
 =
 84
As
th
m
a
N
 =
 59
CO
PD
N
 =
 25
Ag
e
54
50
65
Ge
nd
er
 F
/M
46
/3
8
34
/2
5
12
/1
3
BM
I
29
30
28
Sm
ok
in
g s
tat
us
 n/
e/c
39
/3
6/
9
39
/1
9/
1
0/
8/
17
Sm
ok
in
g p
ac
k y
ea
r 
hi
sto
ry
14
4
40
SP
T
–
2
–
IC
S 
(µ
g)
77
0
77
0
81
0
LA
BA
56
39
17
LA
M
A
26
8
18
LT
RA
 
20
20
0
TH
EO
2
2
0
OA
H
25
24
1
AC
Q
–
1.6
0
–
FE
V 1
 (%
 pr
ed
ict
ed
)
81
88
64
FE
F 2
5–
75
 (%
 pr
ed
ict
ed
)
45
54
24
FV
C 
(%
 pr
ed
ict
ed
)
10
1
10
2
99
FE
V1
/F
VC
 ra
tio
0.6
6
0.7
2
0.5
2
IO
S
AO
S
IO
S
AO
S
IO
S
AO
S
R5
 (k
Pa
/l.
s)
0.5
2
0.5
0
0.5
0
0.4
9
0.5
8
0.5
3
R2
0(
19
) (
kP
a/l
.s)
0.3
7
0.3
6
0.3
7
0.3
6
0.3
8
0.3
6
R5
–R
20
(1
9)
 (k
Pa
/l.
s)
0.1
5
0.1
5
0.1
3
0.1
3
0.2
0
0.1
7
AX
 (k
Pa
/l)
1.4
2
2.4
7
1.1
0
1.9
6
2.1
3
3.5
9
X5
 (k
Pa
/l.
s)
− 
0.2
3
− 
0.2
9
− 
0.2
0
− 
0.2
4
− 
0.2
9
− 
0.4
0
Fr
es
 (H
z)
18
.63
23
.62
17
.38
21
.96
21
.43
27
.35
 Lung
1 3
Lung 
1 3
fit for R5 (R2 = 0.06, p < 0.05) and for R20(19) (R2 = 0.07, 
p < 0.05). The degree of comparative bias between devices 
was small showing relatively higher values with IOS, and 
such differences were significant for post-bronchodilator R5, 
R20(19) and R5–R20(19) (Table 2). Regression analysis of 
IOS versus AOS values for R5 and R20(19) showed highly 
significant model fits along with narrow confidence inter-
vals, R2 and ICC values exceeding 0.7 and 0.9, respectively 
(Table 2 and Fig. 2). Similar results between IOS versus 
AOS were obtained for a subset of n = 58 patients who had 
R20 measured with AOS: R2 = 0.83, p < 0.001, ICC = 0.95, 
mean difference = 0.034  kPa/l.s (95% CI 0.023, 0.045; 
p < 0.001).
Bland–Altman plots for reactance showed poor agree-
ment between IOS and AOS for AX and X5 along with 
a similar trend for Fres (Fig. 1). Regression analysis of 
the Bland–Altman differences between devices showed a 
highly significant model fit for AX: (R2 = 0.66, p < 0.001), 
X5 (R2 = 0.56, p < 0.001) and Fres (R2 = 0.29, p < 0.001). 
The degree of comparative bias between devices was large 
showing relatively higher values with AOS for AX and Fres 
and lower values for X5, with highly significant differences 
in both pre- and post-bronchodilator values (Table 2). As 
expected, mean differences between devices were smaller 
for post- compared to pre-bronchodilator values of AX, X5 
and Fres.
Regression analysis of IOS versus AOS showed a highly 
significant model fit with wider confidence intervals at 
higher AX and Fres values and at lower X5 values. R2 val-
ues ranged between 0.6 and 0.8 and ICC values between 0.8 
and 0.9 (Table 2, Fig. 2).
Looking at asthma and COPD patients separately, the 
same trend was seen in terms of comparative bias between 
device for post-bronchodilator values, with relatively higher 
R5 (p < 0.05), R20(19) (p < 0.05) for IOS, along with higher 
AX (p < 0.05), and lower X5 (p < 0.01) for AOS (Table 2). 
The magnitude of differences between devices for resistance, 
reactance and Fres were all greater in patients with COPD 
than in asthma.
The % reversibility was similar for  FEV1 comparing 
asthma (8.14%) and COPD (8.40%), while for AX the degree 
of reversibility was more pronounced in asthma than COPD 
with AOS: 40% versus 24% (p < 0.05) and IOS: 32% versus 
19% (p > 0.05).
Regression analysis for post-bronchodilator AX and X5 
in relation to  FEV1% predicted in the overall population 
showed a highly significant model fit of moderate effect size 
for both devices (Fig. E1). However, post-bronchodilator AX 
exhibited a weaker model fit in relation to ACQ for either 
IOS (R2 = 0.16, p < 0.01) or AOS (R2 = 0.04, p = 0.143). ROC 
analysis for post-bronchodilator R5 showed a significant 
AUC for IOS but not AOS in relation to ACQ value of 0.75: 
AUC = 0.75 (95% CI 0.61, 0.89), p < 0.01, sensitivity = 0.79, 
specificity = 0.6, for a R5 cut point of 0.36 kPa/l.s. ROC 
analysis for post-bronchodilator AX showed a significant 
AUC for IOS but not AOS in relation to ACQ value of 1.0: 
AUC = 0.66 (95% CI 0.51, 0.81), p < 0.05, sensitivity = 0.62, 
specificity = 0.62, for a AX cut point of 0.52 kPa/l.
Discussion
The main findings of the present study were a small degree 
of comparative bias between devices for resistance as R5 
and R20(19) with relatively higher values being reported 
with IOS. Conversely, respective values for reactance (as 
X5 and AX) and Fres were relatively higher with AOS 
but to a much larger extent. For the combined population 
of asthma and COPD patients, there was good agreement 
from the Bland–Altman analysis between IOS and AOS for 
resistance measured at 5 Hz and 20(19)Hz with a small but 
significant bias in terms of higher post-bronchodilator val-
ues with IOS versus AOS at both frequencies. The mean 
differences in R5 and R5–R20(19) prior to salbutamol were 
not however statistically significant, presumably reflecting 
the wider variance associated with larger pre-bronchodilator 
resistance values.
In the combined population for reactance, there was a 
much higher degree of comparative bias between devices 
for AX and X5 values pre and post salbutamol, which was 
also mirrored by the difference in Fres. This was clearly 
evident from regression analysis of the Bland–Altman plots 
where there was a highly significant model fit for the dif-
ferences. On inspection, the divergence in values between 
devices became more apparent at higher values of AX above 
2 kPa/l. To put this degree of bias in context, the overall 
mean difference in pre-bronchodilator AX was 1.04 kPa/l 
amounting to a 73% higher value for AOS than IOS, while 
for post-bronchodilator AX the difference was 0.64 kPa/l, 
representing a 65% respective higher value. We believe the 
magnitude of such difference in AX is likely to be clini-
cally relevant, although we duly acknowledge the lack of 
any defined minimal clinically important difference values.
The higher AX values seen with AOS than IOS at first 
glance might infer that AOS is more sensitive at detecting 
changes in low frequency reactance, in turn suggesting 
that the IOS is perhaps under reading compared to AOS. 
We believe that this is more likely to be the case than over 
reading with AOS per se. One possible explanation for the 
reactance bias is that the pulsed waveforms with IOS are 
based around a fundamental frequency of 5 Hz, with lower 
amplitudes occurring at higher frequencies. In contrast, 
Fig. 1  Bland–Altman plots in all patients (i.e. asthma and COPD) 
showing post-bronchodilator values of a R5; b R20 (19); c AX; d X5 
and e Fres. The conversion factor from kPa to  cmH2O is × 10.2
◂
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AOS exhibits equivalent amplitudes across a range of non-
harmonic prime frequencies and may therefore be less sus-
ceptible to distortion. Differences in factory calibration 
settings and breathing patterns might in part explain the 
small bias observed in resistance between devices but are 
unlikely to account for the much larger bias in reactance. 
One possible solution would be to have defined reference 
standards for both reactance and resistance in regard to 
device calibration.
One of the strengths of our study was the inclusion of 
both asthma and COPD patients which resulted in being able 
to compare the devices over a wide range of reactance and 
resistance values. On the other hand, a weakness is that we 
did not have a comparator group of healthy controls. Soares 
Table 2  Comparison of IOS and AOS measurements
BD bronchodilator (salbutamol 400 µg), ICC intra-class correlation coefficient. R5 resistance at 5 Hz, R20 resistance at 20 Hz, AX area under the 
reactance curve, X5 reactance at 5 Hz, Fres resonant frequency
† p < 0.001 for regression model fit
*p < 0.05; **p < 0.001 for mean difference IOS–AOS
IOS versus AOS R2 ICC Mean diff (CI)
Pre BD Post BD Pre BD Post BD Pre BD Post BD
Overall
 R5 (kPa/l.s) 0.74† 0.79† 0.92 0.94 0.018
(− 0.002, 0.038)
0.046
(0.030, 0.061)**
 R20(19) (kPa/l.s) 0.74† 0.77† 0.92 0.93 0.016
(0.005, 0.027)*
0.033
(0.023, 0.043)**
 R5–R20(19) (kPa/l.s) 0.68† 0.66† 0.90 0.90 0.003
(− 0.012, 0.017)
0.012
(0.001, 0.023)*
 AX (kPa/l) 0.70† 0.78† 0.84 0.85 − 1.042
(− 1.323, − 0.762)**
− 0.639
(− 0.852, − 0.426)**
 X5 (kPa/l.s) 0.63† 0.65† 0.82 0.80 0.061
(0.034, 0.089)**
0.033
(0.010, 0.056)*
 Fres (Hz) 0.81† 0.82† 0.92 0.93 − 4.990
(− 5.773, − 4.210)**
− 3.666
(− 4.353, − 2.980)**
Asthma
 R5 (kPa/l.s) 0.72† 0.73† 0.92 0.92 0.006
(− 0.018, 0.029)
0.035
(0.016, 0.053)**
 R20(19) (kPa/l.s) 0.73† 0.75† 0.92 0.93 0.015
(0.004, 0.027)*
0.025
(0.015, 0.036)**
 R5–R20(19) (kPa/l.s) 0.69† 0.52† 0.91 0.84 − 0.009
(− 0.025, 0.008)
0.008
(− 0.005, 0.022)
 AX (kPa/l) 0.59† 0.57† 0.78 0.71 − 0.857
(− 1.195, − 0.518)**
− 0.443
(− 0.668, − 0.218)**
 X5 (kPa/l.s) 0.47† 0.49† 0.77 0.70 0.040
(0.010, 0.070)*
0.011
(− 0.013, 0.036)
 Fres (Hz) 0.77† 0.79† 0.92 0.91 − 4.578
(− 5.560, − 3.596)**
− 3.405
(− 4.217, − 2.593)**
COPD
 R5 (kPa/l.s) 0.79† 0.86† 0.94 0.96 0.047
(0.013, 0.082)*
0.071
(0.044, 0.098)**
 R20(19) (kPa/l.s) 0.75† 0.82† 0.92 0.94 0.018
(− 0.006, 0.042)
0.051
(0.029, 0.072)**
 R5–R20(19) (kPa/l.s) 0.66† 0.76† 0.89 0.93 0.029
(0.001, 0.057)*
0.021
(0.004, 0.039)*
 AX (kPa/l) 0.78† 0.84† 0.87 0.88 − 1.453
(− 1.949, − 0.956)**
− 1.105
(− 1.559, − 0.651)**
 X5 (kPa/l.s) 0.76† 0.66† 0.85 0.83 0.111
(0.054, 0.168)*
0.083
(0.035, 0.131)*
 Fres (Hz) 0.83† 0.78† 0.92 0.92 − 5.922
(− 7.195, − 4.649)**
− 4.272
(− 5.614, − 2.930)**
Lung 
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Fig. 2  Scatter plot in all patients (i.e. asthma and COPD) of a R5; b 
R20(19); c AX; d X5 and e Fres showing linear regression line of 
best fit and 95% CI for IOS versus AOS. R2 and intra-class correla-
tion coefficient (ICC) values were R5 R2 = 0.79, ICC = 0.94; R20(19) 
R2 = 0.77, ICC = 0.93; AX R2 = 0.78, ICC = 0.85; X5 R2 = 0.65, 
ICC = 0.8; Fres R2 = 0.82, ICC = 0.93 (p < 0.001 for all regression 
models). The conversion factor from kPa to  cmH2O is × 10.2
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et al. [20] compared the same IOS and AOS devices includ-
ing two age-matched control groups, one non-smokers and 
the other symptomatic current smokers. They observed the 
same overall trends of comparative bias as we did, amount-
ing to mean differences in post-bronchodilator R5 and AX 
of 0.03 kPa/l.s and 0.16 kPa/l respectively in non-smok-
ers, 0.06 kPa/l.s and 0.33 kPa/l respectively in smokers, 
0.04 kPa/l.s and 1.08 kPa/l respectively in asthma. Thus, 
the degree of measurement bias for reactance appeared to 
increase with worsening airflow obstruction. These differ-
ences between IOS and AOS were also reproduced using 
a phantom 3D printed airway resistance model and with a 
standard volume reactance. Hence, their data confirmed the 
comparative bias for AOS in regard to relatively higher AX 
values even in healthy subjects, albeit with a greater differ-
ence in AX occurring in patients with airflow obstruction.
A robust aspect of our data was being able to report 
pre- and post-bronchodilator values when comparing IOS 
and AOS. As expected we found that the mean differences 
between devices were smaller for post- compared to pre-
bronchodilator values of AX and Fres. In other words, giving 
a bronchodilator improves the variance between devices. We 
also found that percentage reversibility response to salbu-
tamol was relatively larger in asthma compared to COPD 
for AX but not for  FEV1. The apparent lack of difference 
in reversibility between asthma and COPD for  FEV1 may 
explained by patients with asthma having a well-preserved 
pre-bronchodilator  FEV1 of 88% predicted, such that there 
was relatively little room for improvement in response to 
salbutamol. The greater sensitivity of FOT than spirometry 
in detecting reversibility is well documented and may be 
explained by the effect of deep inspiration with spirometry 
which removes the prevailing vagal bronchomotor tone [21]. 
It has been shown previously in response to either broncho-
constrictor or bronchodilator stimuli that FOT has an excel-
lent signal-to-noise ratio expressed as standardised response 
means, in both asthma and COPD [22, 23].
A potential limitation of our study is that we did not 
measure serial changes to see if the degree of bias remains 
constant over time. Without such longitudinal data, we are 
unable to speculate whether the measurement bias would 
remain constant over time. We also acknowledge that we 
did not have any information on exacerbation history in 
our patients. However, in patients with asthma, ACQ has 
been shown to being a strong predictor of future exacer-
bations [24]. Moreover, AX and R5–R20 are known to be 
predictive of asthma control and exacerbations [9, 11]. 
We routinely perform IOS in addition to spirometry in all 
patients with asthma and COPD who attend our clinic. 
However, we did not evaluate within breath analysis of 
impedance as this is more of a research tool and something 
which is not performed in clinic. Aside from the reactance 
bias, there are some other key differences between AOS 
and IOS devices, in particular the Tremoflo being cheaper, 
portable and more user friendly for operator and patient 
alike.
In summary, our study showed evidence of better agree-
ment for resistance than reactance when comparing IOS and 
AOS, perhaps inferring that AOS may be more sensitive at 
measuring reactance in patients with airflow obstruction.
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